keyword
https://read.qxmd.com/read/38656784/intravenous-versus-subcutaneous-infliximab-in-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis
#1
JOURNAL ARTICLE
John David Chetwood, Yvonne Tran, Sreedhar Subramanian, Philip J Smith, Marisa Iborra, Anthony Buisson, Sudarshan Paramsothy, Rupert W Leong
BACKGROUND: Subcutaneous (SC) infliximab may provide multiple benefits over intravenous (IV) formulations. However, studies for efficacy and safety in inflammatory bowel disease (IBD) have been constrained by small sizes that limit the interpretation of outcomes, especially for subgroups potentially at high-risk of disease relapse. METHODS: We conducted a systematic review and random-effects meta-analysis up to January 2023 to evaluate the change in clinical remission after transitioning from IV to SC infliximab in patients with IBD in clinical remission...
April 24, 2024: Journal of Crohn's & Colitis
https://read.qxmd.com/read/38656653/systematic-literature-review-on-the-incidence-of-herpes-zoster-in-populations-at-increased-risk-of-disease-in-the-eu-eea-switzerland-and-the-uk
#2
JOURNAL ARTICLE
Alen Marijam, Nikki Vroom, Amit Bhavsar, Inga Posiuniene, Nicolas Lecrenier, Hilde Vroling
INTRODUCTION: Older adults and patients with underlying conditions such as immunocompromised (IC) populations (e.g., due to medical conditions or immunosuppressive medication) are at increased risk for herpes zoster (HZ). The first HZ recombinant vaccine for IC patients was approved in 2020. Limited evidence exists to inform decision-makers on HZ incidence in high-risk patients in Europe. This systematic literature review (SLR) assessed HZ incidence across 14 high-risk populations in the European Union/European Economic Area, Switzerland, and the United Kingdom...
April 24, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38656421/pneumocystis-jirovecii-pneumonia-complicating-use-of-upadacitinib-in-a-patient-with-ulcerative-colitis-and-primary-sclerosing-cholangitis-a-case-report
#3
JOURNAL ARTICLE
Simone Chin, Lucy Fox, Avik Majumdar, Mark Oliver, Matthew C Choy, Peter De Cruz
No abstract text is available yet for this article.
April 24, 2024: Inflammatory Bowel Diseases
https://read.qxmd.com/read/38656096/enterococcus-faecium-supplementation-prevents-enteritis-caused-by-escherichia-coli-in-goats
#4
JOURNAL ARTICLE
J Dong, Y Jiang, Z Li, K Liu, L Guo, L Cui, H Wang, J Li
The probiotic Enterococcus faecium is a gut microbe with immunomodulatory effects, which has been widely used to prevent diarrhoea in pigs and birds. Escherichia coli is a common pathogen that causes inflammatory bowel disease in animals. The aim of this study was to investigate the protective effects of E. faecium on enteritis in goats. Forty goats were randomly divided into 4 treatment groups: control, E. faecium, E. coli, and E. faecium + E. coli. The changes of physiological indicators and diarrhoea scoring were evaluated on days -4, -2, 0, 2, 4, 6, and 8...
October 30, 2023: Beneficial Microbes
https://read.qxmd.com/read/38655866/efficacy-of-dose-escalation-of-oral-5-aminosalicylic-acid-for-ulcerative-colitis-with-a-mayo-endoscopic-subscore-of-1-an-open-label-randomized-controlled-trial
#5
JOURNAL ARTICLE
Tomohiro Fukuda, Yasuhiro Aoki, Hiroki Kiyohara, Ayumi Yokoyama, Atsushi Nakazawa, Yusuke Yoshimatsu, Shinya Sugimoto, Kosaku Nanki, Yohei Mikami, Kayoko Fukuhara, Shinta Mizuno, Tomohisa Sujino, Makoto Mutaguchi, Kaoru Takabayashi, Yuichi Morohoshi, Yasuo Hosoda, Haruhiko Ogata, Yasushi Iwao, Makoto Naganuma, Takanori Kanai
BACKGROUND: Endoscopic healing is generally defined as Mayo endoscopic subscore (MES) ≤1 in ulcerative colitis (UC). However, patients with an MES of 1 are at higher relapse risk than those with an MES of 0. This study evaluated the therapeutic efficacy of proactive dose escalation of oral 5-aminosalicylic acid (5-ASA) in UC patients with an MES of 1. METHODS: An open-label, randomized controlled trial was conducted in 5 hospitals between 2018 and 2022. Ulcerative colitis patients in clinical remission under oral 5-ASA therapy and diagnosed as having an MES of 1 were enrolled...
April 24, 2024: Inflammatory Bowel Diseases
https://read.qxmd.com/read/38655853/systematic-review-and-meta-analysis-impact-of-depression-on-prognosis-in-inflammatory-bowel-disease
#6
REVIEW
Yuejin Ji, Hongxiao Li, Guoliang Dai, Xu Zhang, Wenzheng Ju
BACKGROUND AND AIM: Depression is highly prevalent in patients with inflammatory bowel disease (IBD), which may affect the prognosis of IBD. This aimed to investigate the impact of depression on prognosis in IBD. METHODS: A systematic literature search was performed in four databases (Medline, Embase, Web of Science, and PsycINFO) up to December 31, 2023. Studies were included if they investigated the impact of depression on prognosis in IBD. The primary outcome was flare in IBD, and secondary outcomes were hospitalization, readmission, emergency visits, surgery, and escalation of medical therapy...
April 24, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38655569/vaginal-delivery-in-women-with-perianal-crohn-s-disease-why-not
#7
JOURNAL ARTICLE
Irene J Schaafsma, Froukje J Hoogenboom, Gerard Dijkstra, Jelmer R Prins, Marijn C Visschedijk
BACKGROUND: Pregnant women with active perianal Crohn's disease indicate a cesarean delivery according to the current European Crohn's and Colitis Organisation guidelines. This advice is based on the assumption that vaginal delivery leads to exacerbation of perianal disease and worsening of fecal continence. However, there is no strong evidence to support this. OBJECTIVE: This study aims to examine the effects of the delivery method on perianal disease progression and fecal incontinence in women with perianal Crohn's disease...
May 2024: AJOG global reports
https://read.qxmd.com/read/38655181/antibiotics-influence-the-risk-of-anti-drug-antibody-formation-during-anti-tnf-therapy-in-chinese-inflammatory-bowel-disease-patients
#8
JOURNAL ARTICLE
Meng Sun, Jingyi Ju, Hongzhen Xu, Mengqi Luo, Zhaoyang Li, Yufang Wang
Aims: The formation of anti-drug antibodies (ADAs) during anti-tumor necrosis factor (anti-TNF) therapy is reported to lead to reducing serum drug levels, which may bring about a loss of response to treatment. Previous research has suggested an association between specific antibiotic classes and ADA formation during anti-TNF therapy. However, there are few studies specifically examining this association in Chinese inflammatory bowel disease (IBD) patients. Therefore, our study aimed to evaluate the possible effect of antibiotic use on ADA formation to anti-TNF therapy in Chinese patients with IBD...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38655034/long-term-real-world-data-of-ustekinumab-in-crohn-s-disease-the-stockholm-ustekinumab-study
#9
JOURNAL ARTICLE
Francesca Bello, Samer Muhsen, Haider Sabhan, Alexandra Borin, Fredrik Johansson, Charlotte Höög, Ole Forsberg, Christina Wennerström, Charlotte Söderman, Mikael Lördal, Sven Almer
BACKGROUND: Ustekinumab is used to treat inflammatory bowel disease mainly in patients failing anti-tumour necrosis factor (TNF)-agents. OBJECTIVES: To provide real-world data in unselected patients with Crohn's disease (CD), treated with ustekinumab. DESIGN: Longitudinal retrospective study at four hospitals in Stockholm, Sweden. METHODS: Disease activity (Harvey-Bradshaw index and physician global assessment), laboratory parameters, endoscopic findings and drug persistence were assessed...
2024: Therapeutic Advances in Gastroenterology
https://read.qxmd.com/read/38654396/bayesian-compositional-models-for-ordinal-response
#10
JOURNAL ARTICLE
Li Zhang, Xinyan Zhang, Justin M Leach, Akm F Rahman, Nengjun Yi
Ordinal response is commonly found in medicine, biology, and other fields. In many situations, the predictors for this ordinal response are compositional, which means that the sum of predictors for each sample is fixed. Examples of compositional data include the relative abundance of species in microbiome data and the relative frequency of nutrition concentrations. Moreover, the predictors that are strongly correlated tend to have similar influence on the response outcome. Conventional cumulative logistic regression models for ordinal responses ignore the fixed-sum constraint on predictors and their associated interrelationships, and thus are not appropriate for analyzing compositional predictors...
April 23, 2024: Statistical Methods in Medical Research
https://read.qxmd.com/read/38653907/contributions-of-synthetic-chemicals-to-autoimmune-disease-development-and-occurrence
#11
REVIEW
Noelle N Kosarek, Emma V Preston
PURPOSE OF REVIEW: Exposure to many synthetic chemicals has been linked to a variety of adverse human health effects, including autoimmune diseases. In this scoping review, we summarize recent evidence detailing the effects of synthetic environmental chemicals on autoimmune diseases and highlight current research gaps and recommendations for future studies. RECENT FINDINGS: We identified 68 recent publications related to environmental chemical exposures and autoimmune diseases...
April 24, 2024: Current Environmental Health Reports
https://read.qxmd.com/read/38653566/safety-of-biologics-and-small-molecules-for-inflammatory-bowel-diseases-in-organ-transplant-recipients
#12
JOURNAL ARTICLE
Ga Hee Kim, Minjun Kim, Kyuwon Kim, Jung-Bin Park, Ji Eun Baek, June Hwa Bae, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
PURPOSE: This study aimed to evaluate the safety of biologics and small molecules for the treatment of inflammatory bowel diseases (IBD) in patients receiving antirejection therapies after organ transplants. MATERIALS AND METHODS: We reviewed the medical records of patients with IBD who received organ transplants at the Asan Medical Center between January 1989 and December 2021. We compared the parameters of patients receiving biologics or small molecules to those of patients without those therapies...
May 2024: Yonsei Medical Journal
https://read.qxmd.com/read/38653494/segmental-colectomy-in-ulcerative-colitis
#13
JOURNAL ARTICLE
Sumeyye Yilmaz, Rebecca L Gunter, Arielle E Kanters, David R Rosen, Jeremy Lipman, Stefan D Holubar, Tracy L Hull, Scott R Steele
BACKGROUND: Segmental colectomy in ulcerative colitis is performed in select patients who may be at increased risk for postoperative morbidity. OBJECTIVE: To identify ulcerative colitis patients who underwent segmental colectomy and assess their postoperative and long-term outcomes. DESIGN: Retrospective case series. SETTING: A tertiary-care inflammatory bowel disease center. PATIENTS: Ulcerative colitis patients who underwent surgery between 1995 and 2022...
April 23, 2024: Diseases of the Colon and Rectum
https://read.qxmd.com/read/38652966/the-histamine-h-4-receptor-antagonist-1-5-chloro-2-3-dihydro-1-benzofuran-2-yl-methyl-4-methyl-piperazine-lins01007-prevents-the-development-of-dss-induced-colitis-in-mice
#14
JOURNAL ARTICLE
Beatriz K Lippi, Gustavo A B Fernandes, Gabriela A Azevedo, Nathani G S Negreiros, Antonio W Soares, Maristella A Landgraf, João Paulo S Fernandes, Richardt G Landgraf
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with growing incidence worldwide. Our group reported the compound 5-choro-1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazine (LINS01007) as H4 R antagonist (pKi 6.2) and therefore the effects and pharmacological efficacy on a DSS-induced mice model of UC were assessed in this work. Experimental acute colitis was induced in male BALB/c mice (n = 5-10) by administering 3 % DSS in the drinking water for six days. The test compound LINS01007 was administered daily i...
April 22, 2024: International Immunopharmacology
https://read.qxmd.com/read/38652768/editorial-is-it-time-to-include-oral-vancomycin-in-therapeutic-guidelines-for-primary-sclerosing-cholangitis-associated-inflammatory-bowel-disease
#15
EDITORIAL
Ayesha Shah, Gerald Holtmann
No abstract text is available yet for this article.
May 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38651930/reduction-of-product-composition-variability-using-pooled-microbiome-ecosystem-therapy-and-consequence-in-two-infectious-murine-models
#16
JOURNAL ARTICLE
Julie Reygner, Johanne Delannoy, Marie-Thérèse Barba-Goudiaby, Cyrielle Gasc, Benoît Levast, Enora Gaschet, Laurent Ferraris, Stéphane Paul, Nathalie Kapel, Anne-Judith Waligora-Dupriet, Frederic Barbut, Muriel Thomas, Carole Schwintner, Bastien Laperrousaz, Nathalie Corvaïa
Growing evidence demonstrates the key role of the gut microbiota in human health and disease. The recent success of microbiotherapy products to treat recurrent Clostridioides difficile infection has shed light on its potential in conditions associated with gut dysbiosis, such as acute graft-versus-host disease, intestinal bowel diseases, neurodegenerative diseases, or even cancer. However, the difficulty in defining a "good" donor as well as the intrinsic variability of donor-derived products' taxonomic composition limits the translatability and reproducibility of these studies...
April 23, 2024: Applied and Environmental Microbiology
https://read.qxmd.com/read/38651786/sarm1-controls-the-myd88-mediated-inflammatory-responses-in-inflammatory-bowel-disease-via-the-regulation-of-traf3-recruitment
#17
JOURNAL ARTICLE
Huijuan Fan, Chun Song, Jingyu Zhang
BACKGROUND: Sterile alpha and TIR motif-containing 1 (Sarm1) is known as a negative regulator of inflammatory responses. However, its role in inflammatory bowel disease (IBD) is still unclear. OBJECTIVE: This study aimed to explore the function of Sarm1 in IBD and its underlying mechanisms. Sarm1 and tumor necrosis factor (TNF) receptor associated factor 3 (TRAF3) knockout (KO) micewere established. METHODS: The colitis was induced using dextran sulfate sodium (DSS)...
April 23, 2024: Immunological Investigations
https://read.qxmd.com/read/38651771/meta-analysis-persistence-of-advanced-therapies-in-the-treatment-of-inflammatory-bowel-disease
#18
REVIEW
Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W Leong
BACKGROUND: The expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges in treatment selection. Persistence analysis assesses drug durability in real-world settings, acting as a surrogate marker for medication efficacy and tolerance. Unlike traditional comparative studies, persistence analysis provides insights extending beyond the initial year of treatment. AIM: To provide real-world evidence on treatment effectiveness, tolerability and preferences of physicians and patients regarding various advanced therapies for IBD...
April 23, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38651743/predictors-of-irritable-bowel-syndrome-like-symptoms-in-quiescent-inflammatory-bowel-disease
#19
JOURNAL ARTICLE
Mehwish Ahmed, Autumn Pu, Kara Jencks, Shrinivas Bishu, Peter Higgins, William D Chey, Krishna Rao, Allen Lee
BACKGROUND: Many patients with quiescent inflammatory bowel disease (IBD) suffer from irritable bowel syndrome (IBS)-like symptoms. Although these symptoms cause significant reductions in quality of life, evidence-based treatments are lacking as risk factors and pathophysiology of these symptoms are not clearly defined. We aimed to identify risk factors for development of IBS-like symptoms in IBD patients with quiescent disease. METHODS: We performed a single-center retrospective cohort study of adults with IBD from 2015 to 2021...
April 23, 2024: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://read.qxmd.com/read/38651614/risk-factors-for-surgery-in-stricturing-small-bowel-crohn-s-disease-a-retrospective-cohort-study-from-the-getaid-p%C3%A3-diatrique
#20
JOURNAL ARTICLE
Edouard Lacotte, Louis Boujonnier, Christine Martinez-Vinson, Jérôme Viala, Delphine Ley, Stéphanie Coopman, Héloïse Lerisson, Alain Dabadie, Clémentine Dumant-Forrest, Bénédicte Pigneur, Frank Ruemmele, Raphael Enaud, Aurélie Comte, Julie Rebeuh, Valérie Bertrand, Nicolas Caron, Anne Breton, Rémi Duclaux-Loras, Ioana Vasies, Claire Dupont-Lucas
OBJECTIVES: Previous studies have shown rates of surgical resection of up to 41% in stricturing pediatric Crohn's disease. In this retrospective multicenter study, our aims were to identify clinical risk factors and magnetic resonance enterography (MRE) features of small bowel strictures associated with surgery. METHODS: Pediatric patients with symptomatic stricturing small bowel CD (defined as obstructive symptoms or proximal dilatation on MRE) confirmed by MRE between 2010 and 2020 were recruited from 12 French tertiary hospitals...
April 23, 2024: Journal of Pediatric Gastroenterology and Nutrition
keyword
keyword
833
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.